PT  - JOURNAL ARTICLE
AU  - Sato, Hirofumi
AU  - Murakami, Sei
AU  - Horii, Yusuke
AU  - Nishimura, Go
AU  - Iwai, Ryosuke
AU  - Goto, Moritaka
AU  - Takahashi, Naoki
TI  - Upacicalcet is a novel secondary hyperparathyroidism drug that targets the amino acid binding site of calcium-sensing receptor
AID  - 10.1124/molpharm.122.000522
DP  - 2022 Jan 01
TA  - Molecular Pharmacology
PG  - MOLPHARM-AR-2022-000522
4099  - http://molpharm.aspetjournals.org/content/early/2022/08/05/molpharm.122.000522.short
4100  - http://molpharm.aspetjournals.org/content/early/2022/08/05/molpharm.122.000522.full
AB  - The human calcium-sensing receptor (CaSR) is a G-protein-coupled receptor that maintains extracellular Ca2+ homeostasis by regulating the secretion of parathyroid hormone. Upacicalcet is a novel positive allosteric modulator of CaSR that is used for the treatment of secondary hyperparathyroidism. In the present study, to clarify the binding site of upacicalcet to CaSR, we conducted binding studies and agonistic activity studies in HEK-293T cells expressing human CaSR (intact and mutant), and in silico docking-simulation analysis. As a result, upacicalcet competed with L-tryptophan and was thought to affect the amino acid binding site. In addition, the effects of substitutions at the amino acid binding site on the binding abilities to upacicalcet as well as the effects on receptor function as measured using IP-1 accumulation. Upacicalcet interacted with several CaSR residues that constitute the amino acid binding site. Based on these results, we performed an in silico analysis and obtained a binding mode, consistent with the in vitro study results. Our study revealed that upacicalcet is a novel SHPT drug that targets the amino acid binding site of CaSR. Upacicalcet is expected to become a new treatment option for secondary hyperparathyroidism because the binding site differs from that of conventional drugs; consequently, it may be effective for patients who are not sensitive to conventional drugs, and it may have a superior safety profile. Significance Statement Upacicalcet interacts with several residues that constitute the amino acid binding site of CaSR and shows a potent positive allosteric activity. This mechanism differs from those of conventional drugs. Therefore, upacicalcet can be regarded as a “novel” SHPT drug that acts on the amino acid binding site of CaSR.